Skip to content
value.today

Taiga Biotechnologies, Inc.

Total raised
$24 M
3 rounds on record
Latest round
$3 M
May 2019
First round on record
May 2014
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Taiga Biotechnologies, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2019$3 MNo. 3$2 to $10 million

Taiga Biotechnologies, Inc.: Raise no. 3, May 2019

Investors in this round

10 investors had bought by the notice of Jun 10, 2019: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $14 M offered; $11 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Brian C. Turner · Executive Officer, Director · President
  • James C. Kelly · Executive Officer · Chief Financial Officer
  • Yosef C. Refaeli · Executive Officer, Director · Chief Executive Officer
  • Daniel C. Ritchie · Director
  • Earl L. Wright · Director
  • Stephen K. Erkenbrack · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by James Kelly, Cfo. Newest notice filed Jun 10, 2019. Read the notice at the SEC.

equitySEC
Mar 2017$9 MNo. 2$2 to $10 million

Taiga Biotechnologies, Inc.: Raise no. 2, Mar 2017

Investors in this round

20 investors had bought by the notice of Mar 27, 2018: 20 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$9 M of $20 M offered; $11 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Brian C. Turner · Executive Officer, Director · President
  • Yosef L. Refaeli · Director, Executive Officer · Chief Executive Officer
  • Daniel L. Ritchie · Director
  • Earl L. Wright · Director
  • James C. Kelly · Director
  • Stephen K. ErkenBrack · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Brian C. Turner, President. Newest notice filed Mar 27, 2018 (1 amendment). Read the notice at the SEC.

equitySEC
May 2014$12 MNo. 1$10 to $50 million

Taiga Biotechnologies, Inc.: Raise no. 1, May 2014

Investors in this round

21 investors had bought by the notice of Jun 3, 2015: 21 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$12 M of $12 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Brian Curtis Turner · Executive Officer, Director
  • Yosef Curtis Refaeli · Executive Officer, Director
  • Daniel L. Ritchie · Director
  • James Curtis Kelly · Director
  • Stephen K. ErkenBrack · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Brian C. Turner, President. Newest notice filed Jun 3, 2015 (1 amendment). Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Taiga Biotechnologies, Inc. chose not to state its revenue in its newest notice of a funding round (Jun 2019).

    SEC Form D · Jun 2019

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jun 2019

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Taiga Biotechnologies, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Taiga Biotechnologies, Inc.
NameRoleNamed in
Brian C. TurnerPresidentJun 2019
James C. KellyChief Financial OfficerJun 2019
Yosef C. RefaeliChief Executive OfficerJun 2019
Yosef L. RefaeliChief Executive OfficerMar 2018
Brian Curtis TurnerExecutive officerJun 2015
Yosef Curtis RefaeliExecutive officerJun 2015
Brian C. TurnerPresidentJun 2019
Daniel C. RitchieDirectorJun 2019
Earl L. WrightDirectorJun 2019
Stephen K. ErkenbrackDirectorJun 2019
Yosef C. RefaeliChief Executive OfficerJun 2019
Daniel L. RitchieDirectorMar 2018
James C. KellyDirectorMar 2018
Stephen K. ErkenBrackDirectorMar 2018
Yosef L. RefaeliChief Executive OfficerMar 2018
Brian Curtis TurnerDirectorJun 2015
James Curtis KellyDirectorJun 2015
Yosef Curtis RefaeliDirectorJun 2015